Newsletter | May 15, 2019

05.15.19 -- Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End

  Biologic Sterile Injectable Drug Product Manufacturing Market Overview And Outlook

This market research report provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents — all outsourcing decision makers — predict the market will look like in 2022. You can purchase the full report or download a free preview by clicking here.

Featured Editorial
Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End
By Robert Browne, Fuld + Company

Within the last few years, the FDA has taken steps to approve more biosimilar products and has committed to providing for a competitive landscape. The three latest biosimilars to be approved by the FDA have all been biosimilars to Herceptin. Further, Pfizer’s Trazimera, the most recently approved trastuzumab biosimilar, has sparked intrigue. As a result, Genentech is bracing for Herceptin biosimilar commercial launches in 2019.

CDMO Selection: 3 Questions To Save Time And Reduce Stress When Reviewing An MSA
By Ray Sison, xCell Strategic Consulting, LLC

Whether because of unfamiliarity or lack of resources, master service or supply agreement (MSA) execution can be time-consuming and difficult. An MSA is not a novel, read from front to back — it is a functional legal document that provides operational, financial, and legal guidance that will be referenced as needed throughout the term of the agreement.

Industry Insights
Pharma Production Tech Transfers: Reaping Rewards, Reducing Risks
White Paper | By Thomas Dax, Mirko Gabriele, and Paul Jorjorian, Thermo Fisher Scientific

Transferring production — and the technologies that undergird it — can be risky. The same product can behave differently in different equipment, resulting in low yields or even batch rejections.

Why, Why, Why … ELISA? A Look At The Benchmark HCP Assay
Article | By Joe Hirano, GE Healthcare Life Sciences

Biologics developers and manufacturers demand an accurate and reliable assay for host cell protein (HCP) quantitation. Let’s take a close look at why analytical scientists turn to the ELISA, and how it fits into process development.

The Strength And Flexibility Of Flexsafe, Flexboy, And Celsius Bags Ensure Their Robustness In All Applications
White Paper | Sartorius Stedim Biotech

The costs are high when leakage occurs during steps that are critical to patient safety. Read how the robustness of Sartorius films makes them safe and easy to use for all process steps and applications.

The Standardization Of Single-Use Components For Bioprocessing
Article | CPC

As single-use systems become more widely adopted, the focus in the bioprocessing industry is shifting from acceptance of the technology to standardization. 

The Biomedicine Revolution
E-Book | Thermo Fisher Scientific

Personalized medicine has the untapped potential to unlock value for both patients and providers. However, biomanufacturers face major obstacles in drug development, such as increasing regulatory oversight, longer development times, and a growing public focus on drug pricing. This e-book outlines some of those struggles as well as highlights the successes of those working to advance the personalized medicine industry.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.

Connect With BioProcess Online: